Cases
Cases
Karyopharm is pursuing a Chapter 11 reorganization with Ayrmid Ltd. while marketing its assets for a competing sale. The court has approved bidding procedures and interim financing; a November 30, 2026 hearing will consider final financing approval and Ayrmid’s proposed bid protections under the financing order Dkt. 61 and bidding procedures order Dkt. 68.
Karyopharm Therapeutics Inc. is pursuing a proposed Chapter 11 reorganization with Ayrmid Ltd. while running a court-supervised process for competing offers. The bidding procedures order Dkt. 68 approves Ayrmid as stalking horse bidder and sets a December 16, 2026 bid deadline. If competing qualified bids are received, an auction is scheduled for December 21; a sale hearing is set for January 11, 2027. Any sale remains subject to court approval.
Karyopharm, a commercial-stage cancer therapeutics company, filed for Chapter 11 on November 2, 2026, alongside affiliate KPT Texas LLC. The disclosure statement Dkt. 18 reports approximately $390 million in funded debt, including accrued interest and fees. The debtors’ proposed plan offers a reorganization or a qualifying sale, subject to the applicable conditions and consents.
Under the proposed reorganization, Karyopharm stakeholders would receive 55% of the post-merger company’s equity, subject to dilution, and Ayrmid equityholders would receive 45%. The plan also proposes an exit facility of up to $135 million in new-money loans. General unsecured claims would remain unimpaired, and existing equity interests would be canceled without a distribution. These treatments remain proposals under the plan Dkt. 17 and disclosure statement Dkt. 18.
The court’s interim financing order Dkt. 61 authorizes up to $25 million in interim new-money borrowing and use of cash collateral. The facility provides for up to $55 million in new money and up to $55 million in rolled-up prepetition loans; the additional $30 million new-money draw and corresponding roll-up depend on a final order and other conditions. A final financing hearing is scheduled for November 30, 2026. Ayrmid’s proposed bid protections are also subject to a further order after a November 30 hearing under the bidding procedures order Dkt. 68.
Updated Nov 13
Case facts and filing dates come from court records.Case docket on PACER